Search

The article focuses on the latest NICE guideline aimed at increasing the number of patients offered statins to reduce cardiovascular risk, discussing detection methods, initiating statin therapy, and optimizing treatment for both primary and secondary prevention of cardiovascular disease (CVD). It emphasizes the importance of systematic risk assessment using tools like QRISK3, baseline tests before initiating statin therapy, and considerations for treatment escalation.

The article focuses on the latest NICE guideline on Cardiovascular disease (CVD) risk assessment and reduction, particularly concerning lipid management targets, which has sparked debate within the Primary Care Cardiovascular Society (PCCS) regarding its alignment with other guidelines and its potential impact on reducing cardiovascular events.

The article presents an interview with Consultant Nephrologist, Robert Lewis, on diagnosis of diabetic renal disease. Topics include how has diabetic kidney disease recognised and how differ from chronic kidney disease in people without diabete; and how has proteinuria reliably detected in practice.

The article discusses the important role of healthcare professionals in reducing the risks of cardiovascular and metabolic diseases in people with serious mental illness (SMI). Topics covered include the association of SMI with the physical health of an individual, details relating to the limited access of people with SMI to health services according to "The Report of the National Audit of Schizophrenia" and the "Positive Cardiometabolic Health Resource 2014" intervention framework.

The article discusses an approach by the Joint British Societies for reducing the burden of cardiovascular disease (CVD) in individuals by promoting a better understanding of risk, improving uptake of lifestyle improvements and improving uptake of preventive therapies. Topics discussed include the introduction of the concept of "lifetime risk" as the key change in the approach in assessing CVD risk and the development of a risk calculator using "QRISK Lifetime" as basis for risk assessment.

The article presents guidelines for practice nurses in Great Britain involving prescribing for lipid modification. According to the National Institute for Health and Clinical Excellence (NICE), simvastatin is the first-line lipid-lowering treatment. Liver function should be measured to check if statins have increased liver enzymes. Alternative drugs for lipid modification are ezetimibe, fibrates, bile acid sequestrants and Omega-3 fish oils.

The article discusses why and for whom lipid-lowering drugs should be prescribed. It explores clinical guidelines published by the British National Institute for Health and Clinical Excellence (NICE) in 2008 that address the prescribing of lipid-lowering agents. The guidance states that statins remain the first-line therapy in most cases in patients who are at high risk of a cardiovascular event, unless they are not tolerated. Lipid-lowering drugs for secondary prevention include ezetimibe, fibrates, nicotinic acid and bile acid sequestrants.

The article discusses the Quality and Outcomes Framework (QOF) indicators for stroke. It describes the epidemiology of stroke in Great Britain, including the rate of mortality associated with stroke. An explanation of the different QOF indicators for stroke is provided, such as confirmation of diagnosis, blood pressure, lipids level, antiplatelet/anticoagulant therapy and influenza immunization.

The author presents case studies in dyslipidaemia and the use of lipid-lowering drugs among patients at high risk of a cardiovascular event. Therapies in line with the current guidance from Great Britain's National Institute for Health and Clinical Excellence are suggested. The author stresses that decisions regarding lipid management and cardiovascular disease risk reduction must be made with the individual patient and after careful appraisal of the risks, benefits, and available alternatives.

The article discusses various issues concerning lipid modification in relation to cardiovascular disease (CVD). It cites the guidance on lipid modification published by Great Britain National Institute for Clinical Excellence (NICE). An explanation on the value of lipid modification in the primary prevention of CVD is offered, along with the factors that affect cholesterol measurement. The article also discusses the pharmacological management of CVD.

The article focuses on a new agenda adopted by the Great Britain Department of Health (DH) that offers health professionals working with patients at high cardiovascular risk and their families the opportunity to put prevention first. The lipid guideline advises on lifestyle and medical modification of lipids in patients with atherosclerotic cardiovascular disease and in those who are at high risk of developing disease. The guideline also recommends that health professionals should focus on total or absolute risk when explaining risk to patients.

The article offers information on niaspan, a once-daily, modified-release form of nicotinic acid. Niaspan has several lipid-modifying actions. It increases high density lipoprotein (HDL) levels by about a quarter on average, achieved in part through reducing the rate of uptake of HDL particles by the liver and hence prolonging their half-life. It benefits the profile of HDL in the circulation by favouring an increase in the cardioprotective HDL2 subtraction.

Focuses on lipid lowering treatment for type 2 diabetics. Risk of developing a first cardiac event in patients; Criteria that must be met by patients to participate in the Collaborative Atorvastatin in Diabetes Study; Effectiveness of atorvastatin with placebo for reducing the risk of coronary heart disease.

Discusses the management of type 2 diabetes. Role of lipids in cardiovascular disease; Identification of patients with type 2 diabetes; Treatment; Risk factors for diabetes; Information on dyslipidaemia.

The article focuses on the use of diet to help reduce lipid levels. Hyperlipidaemia is a major risk factor for cardiovascular disease, such as ischaemic stroke. Dietary modification is the cornerstone of lifestyle strategies that aim to reduce lipid levels. However, the maximum reduction in total cholesterol that most individuals will achieve by following a low fat diet and losing weight is 3 to 6 percent. This suggests a need to look beyond modifying the amount and type of fat in the diet.

The article reports that practice nurses in Great Britain will be expected to hit tough new targets on the identification of people at risk of cardiovascular disease (CVD) and for lipid modification, following the publication of new guidance from the National Institute for Clinical Excellence (NICE). NICE says that practices must adopt a more systematic strategy to identify people who are likely to be at high risk of CVD.

The article presents information on a study stating that lipid levels are significantly associated with ischaemic stroke risk in healthy women. U.S. researchers followed up 27,937 healthy women aged 45 and over for 11 years, during which time they reported 282 ischaemic strokes. Hazard ratios for the total-to high density lipoprotein (HDL)-cholesterol ratio and non-HDL-cholesterol were 1.65 and 2.45, respectively.

The article explains the therapeutic uses of soya beans. Soya is often called the miracle crop because of its versatility as a food source and has been a staple of Eastern diets for over 5,000 years. Soya beans also contain oil which has the ability to mimic the skin's natural lipids, supporting the natural skin barrier function. And their oil has been used in bath oils, creams and lotions to alleviate dry skin associated with eczema. They can be used to make soya milk, tofu, flour and textured protein.

Presents the findings of medical research published in clinical journals. Effect of self-help psychotherapy on patients, from the "British Journal of Psychiatry"; Relationship between lipid levels and cardiovascular risk in older people, from the "Journal of American Geriatric"; Significance of cognitive behaviour therapy to patients with obsessive-compulsive disorder, from the "Journal of the American Medical Association."